Provider-Facing•15 min read•Updated 2026-04-03

    GLP-1 Titration Protocols: Clinical Dose Escalation Guide for Providers

    Evidence-based titration protocols for semaglutide, tirzepatide, and retatrutide. Standard schedules, modified protocols for sensitive patients, and managing dose-limiting side effects.

    More on Provider-Facing

    View all Provider-Facing articles

    Prescriber Guide

    Full prescribing reference

    Side Effect Decision Tree

    SE management

    Clinical Reference

    Standardized titration protocols for GLP-1 agonists including standard and modified (sensitive patient) schedules. Slow titration reduces discontinuation rates by approximately 40% compared to accelerated schedules.

    Titration Schedules

    Semaglutide Standard

    0.25mg (wk 1-4)0.5mg (wk 5-8)1.0mg (wk 9-12)1.7mg (wk 13-16)2.4mg (wk 17+)

    Total time to maximum dose: 16 weeks to max

    Semaglutide Modified (Sensitive)

    0.25mg (wk 1-8)0.5mg (wk 9-16)1.0mg (wk 17-24)1.7mg (wk 25-32)2.4mg (wk 33+)

    Total time to maximum dose: 32 weeks to max

    Tirzepatide Standard

    2.5mg (wk 1-4)5mg (wk 5-8)7.5mg (wk 9-12)10mg (wk 13-16)12.5mg (wk 17-20)15mg (wk 21+)

    Total time to maximum dose: 20 weeks to max

    Tirzepatide Modified (Sensitive)

    2.5mg (wk 1-8)5mg (wk 9-16)7.5mg (wk 17-24)10mg (wk 25-32)12.5mg (wk 33-40)15mg (wk 41+)

    Total time to maximum dose: 40 weeks to max

    Dose Escalation Decision Points

    Proceed to Next Dose When

    • GI side effects resolved or manageable
    • Minimum 4 weeks at current dose completed
    • Appetite returning between doses
    • Weight loss rate slowing at current dose

    Hold or Reduce Dose When

    • Persistent vomiting beyond 2 weeks at dose
    • Dehydration signs despite adequate intake efforts
    • Weight loss exceeding 1 kg/week consistently
    • Elevated lipase/amylase (3x ULN)

    Special Population Considerations

    Elderly Patients (65+)

    Use modified (slower) titration. Monitor renal function more frequently. Emphasize protein intake to prevent sarcopenia. Be vigilant for dehydration. Consider lower maximum dose targets. Monitor for falls risk from orthostatic changes.

    Patients with Renal Impairment

    No dose adjustment required for semaglutide or tirzepatide based on renal function. However, GI side effects increasing dehydration risk can worsen renal function. Monitor eGFR every 3 months. Extra caution with concurrent nephrotoxic medications.

    Patients on Insulin or Sulfonylureas

    Proactively reduce insulin doses by 20-30% when initiating GLP-1 therapy. Consider halving sulfonylurea doses. Monitor blood glucose closely during titration. Hypoglycemia risk is the primary concern. Adjust diabetes medications as weight loss improves glycemic control.

    Clinical Disclaimer: This guide is for licensed healthcare providers. Verify current prescribing information. Individual patient assessment supersedes protocol guidelines. Trimi providers are available for clinical consultation.

    Frequently Asked Questions

    What is the standard semaglutide titration schedule?

    Standard protocol: 0.25mg x 4 weeks, 0.5mg x 4 weeks, 1.0mg x 4 weeks, 1.7mg x 4 weeks, then 2.4mg maintenance. Each step is minimum 4 weeks. Extended stays at any dose are appropriate for GI tolerability. Not all patients require the maximum dose.

    When should I use a modified (slower) titration?

    Consider slower titration for: elderly patients, patients with gastroparesis history, those on medications affecting GI motility, patients with high nausea sensitivity, and those with prior GLP-1 intolerance. Modified protocol doubles the time at each dose level to 8 weeks.

    What indicates a patient has reached their optimal dose?

    Optimal dose criteria: adequate appetite suppression, tolerable side effects, satisfactory weight loss trajectory (minimum 1% per month), patient comfort and adherence. The optimal dose is not necessarily the maximum dose -- many patients achieve excellent results at intermediate doses.

    How should I manage dose-limiting side effects?

    If side effects prevent dose escalation: maintain current dose for additional 4-8 weeks, optimize anti-emetic support, ensure adequate hydration, consider splitting injection technique (half doses twice weekly off-label), or accept current dose as the patient's therapeutic maximum.

    Refer Patients to Trimi

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo with full clinical oversight.

    View Treatment Options

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What's the standard GLP-1 dose titration schedule?

    Per FDA prescribing information, the standard titration schedules are: SEMAGLUTIDE (Wegovy): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, each step held for 4 weeks, total 16 weeks to maintenance. TIRZEPATIDE (Zepbound): 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, each step held for at least 4 weeks, total 20 weeks to maximum. Both schedules are designed to manage gastrointestinal side-effect tolerability — the dose-dependent nausea, vomiting, and diarrhea typically decrease over 2-4 weeks at each step. Clinically recognized variations: slowed titration (extending steps to 5-8 weeks) for patients with severe GI symptoms; holding at lower maintenance doses (1.0-1.7 mg semaglutide; 5-10 mg tirzepatide) when those doses produce adequate weight loss with better tolerability. The titration schedule is set by the prescribing clinician.

    Semaglutide: 5-step titration over 16 weeks (0.25 → 2.4 mg).
    Tirzepatide: 6-step titration over 20 weeks (2.5 → 15 mg).
    Slow / hold-at-lower-dose options recognized for tolerability.

    Key Takeaways

    • Standard semaglutide titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, each step held for 4 weeks (16 weeks total to maintenance).
    • Standard tirzepatide titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, each step held for at least 4 weeks (20 weeks total to maximum).
    • Slowed titration (extending steps to 5-8 weeks) is a clinically recognized strategy for patients experiencing severe GI side effects.
    • Holding at lower maintenance doses (1.0-1.7 mg semaglutide; 5-10 mg tirzepatide) is appropriate when those doses produce adequate weight loss with better tolerability.

    Medically Reviewed

    DMR

    Dr. Michael Rodriguez

    MD, FACP, Board Certified in Internal Medicine

    Internal Medicine & Weight Management

    Last reviewed: January 4, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Dr. Michael Rodriguez, MD, FACP, Board Certified in Internal Medicine

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    — Lynn SchweitzerFacebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    — Robyn Lynn CurtisFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Novo Nordisk (2025). Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration.Read Study
    2. Eli Lilly and Company (2025). Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration.Read Study
    3. The Endocrine Society (2024). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.Read Study

    Was this article helpful?

    Keep Reading

    Provider-Facing

    When to Switch GLP-1 Agents: Clinical Decision Framework for Providers

    Evidence-based criteria for switching between semaglutide, tirzepatide, and retatrutide. Inadequate response definitions, switching protocols, and dose conversion guidelines.

    10 minRead More
    GLP-1

    Semaglutide 0.25mg Starting Dose

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    10 minRead More
    Provider-Facing

    GLP-1 Prescriber Guide: Clinical Reference for Semaglutide, Tirzepatide, and Retatrutide Prescribing

    Comprehensive clinical prescribing reference for GLP-1 receptor agonists covering patient selection, titration protocols, monitoring, contraindications, and evidence-based management strategies.

    10 minRead More
    Provider-Facing

    GLP-1 Perioperative Guide: Pre-Surgical Hold Protocols and Anesthesia Safety

    Clinical guide for managing GLP-1 medications around surgery. ASA guidelines, hold timelines, aspiration risk, and resumption protocols for semaglutide, tirzepatide, and retatrutide.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started